MAPT and Alzheimer disease: However, the key AD biomarkers are traditionally measured with techniques/exams that are either expensive (amyloid-PET and tau-PET), invasive (cerebrospinal fluid (CSF) Aβ42/Aβ40 and p-tau), or poorly specific (atrophy on MRI and hypometabolism on FDG-PET).